spesolimab

Generalized Pustular Psoriasis (GPP)

Spesolimab is used to treat generalized pustular psoriasis (GPP), a rare and severe skin disease. GPP is different from more common types of psoriasis and is characterized by sudden outbreaks of painful, pus-filled blisters that can cover large areas of the body. These episodes, known as flares, may also cause fever, chills, and extreme exhaustion.

Treatment of Active Flares

This medication is prescribed to treat the symptoms of an active GPP flare. It works to help clear the skin pustules and reduce the systemic inflammation associated with the outbreak.

Long-term Management

Spesolimab is also used to treat GPP in patients when they are not currently experiencing a flare. This application focuses on managing the underlying condition in people who are prone to these severe skin episodes.

Patient Eligibility

Spesolimab is approved for use in adults and pediatric patients who meet the following criteria:

• Are at least 12 years of age.
• Weigh at least 40 kg (approximately 88 pounds).

Targeting the IL-36 Pathway

Spesolimab is a humanized monoclonal antibody designed to block a specific pathway in the immune system. It works by binding to the interleukin-36 (IL-36) receptor, which is a protein found on the surface of many cells, including those in the skin.

Reducing Inflammation

In a healthy immune system, the IL-36 receptor helps regulate the body's response to injury or infection. However, in certain conditions like generalized pustular psoriasis (GPP), the signaling through this receptor becomes overactive. This leads to an excessive inflammatory response, causing the skin to develop redness, pain, and pustules.

When spesolimab attaches to the IL-36 receptor, it prevents other inflammatory proteins called cytokines from binding to that same spot. By blocking these signals, the medication helps to:

• Stop the overactive immune response that causes skin flares.
• Reduce the formation of new pustules.
• Decrease overall skin inflammation and redness.

By interfering with this specific part of the immune system, spesolimab addresses the underlying biological cause of GPP symptoms rather than just treating the surface of the skin.

Common Side Effects

• Nausea or vomiting
• Headache
• Feeling tired or weak
• Itching
• Pain, redness, or bruising at the injection site
• Urinary tract infection

Serious Side Effects

Seek medical attention immediately if you experience any of the following serious side effects:

• Infections: Fever, chills, cough, or painful urination. Spesolimab may lower your body's ability to fight infections.
• Allergic reactions: Swelling of the face, lips, or throat; hives; or trouble breathing.
• Infusion or injection reactions: Feeling dizzy or nauseated during or after the procedure.
• Severe skin reactions: A widespread rash that may occur with fever or swollen glands.

Infections

Spesolimab may increase the risk of infections. Treatment is typically not started in individuals with a clinically important active infection until the condition is resolved or properly managed. Healthcare providers monitor for signs and symptoms of infection during and after treatment.

Tuberculosis Screening

Before starting treatment, patients are evaluated for tuberculosis (TB). If a latent TB infection is identified, preventive treatment for TB is generally initiated before the first dose of spesolimab. Monitoring for active TB continues throughout the course of therapy.

Hypersensitivity and Infusion Reactions

Serious allergic reactions, including anaphylaxis, have been reported. If a severe hypersensitivity reaction occurs, the medication is stopped immediately. Symptoms of a reaction may include:

• Difficulty breathing or swelling of the face or throat
• Chest pain or discomfort
• Faintness or dizziness
• Severe rash or hives

Infusion-related reactions may also occur during or shortly after the administration of the drug. If these occur, the infusion may be slowed or stopped.

Vaccinations

Live vaccines should be avoided while using spesolimab. It is recommended that all age-appropriate immunizations be updated according to current guidelines before starting treatment.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

This is a rare but serious systemic reaction that has been associated with spesolimab. It may involve a skin rash along with fever, swollen lymph nodes, and effects on internal organs such as the liver or kidneys.

Pregnancy

Data on the use of spesolimab in pregnant women are limited, and it is not yet known if the medication increases the risk of birth defects, miscarriage, or other adverse outcomes. Animal studies using doses significantly higher than those used in humans did not show evidence of harm to the developing fetus. However, spesolimab is a monoclonal antibody, which is a type of protein known to cross the placenta, particularly during the third trimester of pregnancy.

Breastfeeding

It is not known whether spesolimab passes into human breast milk, how it affects milk production, or if it has any impact on a breastfed infant. Because many medications can be found in breast milk, it is important to consider the benefits of breastfeeding alongside the mother's clinical need for the drug and any potential risks to the infant.

Consulting Your Doctor

If you are pregnant, planning to become pregnant, or breastfeeding, you should discuss your treatment options with your healthcare provider. They can help evaluate the potential risks and benefits based on your specific medical situation.

Injectable Forms

Spesolimab is supplied as a sterile, preservative-free solution in two primary formats:

• Single-dose vial: This form is intended for intravenous infusion. It is a concentrated solution that must be diluted by a healthcare professional before administration.
• Single-dose prefilled syringe: This form is intended for subcutaneous injection.

The medication is a clear to slightly opalescent, colorless to slightly yellow liquid. Each vial or prefilled syringe is designed for single use only, and any remaining portion should be discarded after the dose is administered.

FDA Approval Status

Spesolimab is an interleukin-36 receptor antagonist that received its initial approval from the U.S. Food and Drug Administration (FDA) in September 2022. It was the first medication specifically approved to treat flares of generalized pustular psoriasis (GPP).

Approved Indications

The FDA has approved spesolimab for use in adults and pediatric patients (12 years of age and older who weigh at least 40 kg) for the following indications:

• Treatment of generalized pustular psoriasis flares.
• Treatment of generalized pustular psoriasis when flares are not present, to reduce the risk of future flares (maintenance treatment).

Safety and Regulatory Communications

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) required for spesolimab. However, the FDA-approved labeling includes several important safety precautions:

• Infections: Because the medication affects the immune system, it may increase the risk of infections. Patients must be screened for tuberculosis (TB) before beginning treatment.
• Hypersensitivity: Serious allergic reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported.
• Vaccinations: Patients should avoid receiving live vaccines during treatment and for a period after the final dose.

Factors Influencing Cost

The total cost of spesolimab treatment is affected by whether it is administered as an intravenous infusion in a clinical setting or as a subcutaneous injection. As a specialty medication, it is often managed through specialty pharmacies rather than standard retail locations.

Insurance and Prior Authorization

Insurance providers typically require prior authorization before covering spesolimab. This means a healthcare provider must confirm that the medication is medically necessary for treating generalized pustular psoriasis (GPP) flares. Out-of-pocket expenses like deductibles and copays vary significantly between different insurance plans and tiers.

Patient Assistance Programs

Financial assistance may be available through the drug manufacturer for patients who meet specific eligibility criteria. These programs can include copay savings cards for those with commercial insurance or patient assistance programs for individuals who are uninsured or underinsured. Patients should consult their healthcare team or the manufacturer's support program to determine available options.